DE602005025232D1 - Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion - Google Patents

Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion

Info

Publication number
DE602005025232D1
DE602005025232D1 DE602005025232T DE602005025232T DE602005025232D1 DE 602005025232 D1 DE602005025232 D1 DE 602005025232D1 DE 602005025232 T DE602005025232 T DE 602005025232T DE 602005025232 T DE602005025232 T DE 602005025232T DE 602005025232 D1 DE602005025232 D1 DE 602005025232D1
Authority
DE
Germany
Prior art keywords
treatment
infection
äetvalü4
mealaü3
ciclosporin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005025232T
Other languages
English (en)
Inventor
Pietro Scalfaro
Jean-Maurice Dumont
Gregoire Vuagniaux
Rolland-Yves Mauvernay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Debiopharm SA
Original Assignee
Debiopharm SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm SA filed Critical Debiopharm SA
Publication of DE602005025232D1 publication Critical patent/DE602005025232D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
DE602005025232T 2004-10-01 2005-10-03 Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion Active DE602005025232D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2004003205 2004-10-01
PCT/IB2005/002940 WO2006038088A1 (en) 2004-10-01 2005-10-03 Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin

Publications (1)

Publication Number Publication Date
DE602005025232D1 true DE602005025232D1 (de) 2011-01-20

Family

ID=34959441

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005025232T Active DE602005025232D1 (de) 2004-10-01 2005-10-03 Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion

Country Status (30)

Country Link
US (3) US7439227B2 (de)
EP (1) EP1793844B1 (de)
JP (1) JP4892486B2 (de)
KR (1) KR101191833B1 (de)
CN (1) CN101056648B (de)
AT (1) ATE490778T1 (de)
AU (1) AU2005290984B2 (de)
BR (1) BRPI0515494A (de)
CA (1) CA2580448C (de)
CY (1) CY1114594T1 (de)
DE (1) DE602005025232D1 (de)
DK (1) DK1793844T3 (de)
EA (1) EA012650B1 (de)
ES (1) ES2357587T3 (de)
GE (1) GEP20104960B (de)
HK (1) HK1104236A1 (de)
HR (1) HRP20110169T1 (de)
IL (1) IL182362A0 (de)
MA (1) MA28950B1 (de)
MX (1) MX2007003387A (de)
NZ (1) NZ554412A (de)
PL (1) PL1793844T3 (de)
PT (1) PT1793844E (de)
RS (1) RS51614B (de)
SG (1) SG139750A1 (de)
SI (1) SI1793844T1 (de)
TN (1) TNSN07084A1 (de)
UA (1) UA88484C2 (de)
WO (1) WO2006038088A1 (de)
ZA (1) ZA200702610B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
DE602005026294D1 (de) 2004-07-14 2011-03-24 Novartis Ag Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
ATE412005T1 (de) 2004-11-22 2008-11-15 Astellas Pharma Inc Zyklosporinanalog
CN101076350A (zh) 2004-12-23 2007-11-21 诺瓦提斯公司 用于hcv治疗的组合物
JP2008525458A (ja) * 2004-12-23 2008-07-17 ノバルティス アクチエンゲゼルシャフト フラビウイルス科処置用化合物
JP2008546708A (ja) * 2005-06-17 2008-12-25 ノバルティス アクチエンゲゼルシャフト Ｈｃｖにおけるサングリフェリンの使用
US8329658B2 (en) 2005-09-30 2012-12-11 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
JP5517454B2 (ja) 2005-09-30 2014-06-11 スシネキス インク Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物
ES2557477T3 (es) 2005-10-26 2016-01-26 Astellas Pharma Inc. Nuevos compuestos peptídicos cíclicos
MX2008013119A (es) 2006-04-11 2008-10-21 Novartis Ag Inhibidores de hcv/vih y sus usos.
JP5377293B2 (ja) 2006-05-19 2013-12-25 スシネキス インク 眼疾患の治療及び予防方法
CA2665415A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Use of modified cyclosporins
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
KR20100017547A (ko) 2007-05-02 2010-02-16 아스텔라스세이야쿠 가부시키가이샤 신규 시클릭 펩티드 화합물
CA2700536A1 (en) 2007-09-26 2009-04-02 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009098533A1 (en) * 2008-02-08 2009-08-13 Debiopharm Sa Non -immunosuppressive cyclosporin for the treatment of muscular dystrophy
WO2009148615A1 (en) * 2008-06-06 2009-12-10 Scynexis, Inc. Cyclosporin analogs and their use in the treatment of hcv infections
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
WO2010052559A1 (en) 2008-11-06 2010-05-14 Debio Recherche Pharmaceutique S.A. Cycloundecadepsipeptide compounds and use of said compounds as a medicament
CN102307892A (zh) 2008-12-31 2012-01-04 西尼克斯公司 环孢菌素a的衍生物
CA2751210C (en) 2009-01-30 2015-04-21 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
WO2011070364A1 (en) 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2011141891A1 (en) 2010-05-12 2011-11-17 Debio Recherche Pharmaceutique S.A. Use of cycloundecadepsipeptide compounds
WO2012009715A2 (en) 2010-07-16 2012-01-19 S&T Global Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
US9573978B2 (en) 2010-08-12 2017-02-21 S&T Global, Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
CA2811700A1 (en) * 2010-10-05 2012-04-12 Novartis Ag New treatments of hepatitis c virus infection
US9011833B2 (en) 2010-10-08 2015-04-21 Novartis Ag Vitamin E formulations of sulfamide NS3 inhibitors
CN103221053A (zh) 2010-11-30 2013-07-24 诺华有限公司 丙型肝炎病毒感染的新疗法
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
KR20140007927A (ko) 2011-03-31 2014-01-20 노파르티스 아게 C형 간염 바이러스 감염을 치료하기 위한 알리스포리비르
PL2694087T3 (pl) * 2011-04-01 2015-06-30 Novartis Ag Leczenie zakażenia wirusem zapalenia wątroby typu B samego lub w połączeniu z zakażeniem wirusem zapalenia wątroby typu delta i towarzyszącymi chorobami wątroby
US20150104415A1 (en) 2011-04-13 2015-04-16 Debiopharm International Sa Treatments of Hepatitis C virus infection
EP2760461A1 (de) * 2011-09-27 2014-08-06 Novartis AG Alisporivr zur behandlung von hepatitis-c-virusinfektionen
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
UY34401A (es) 2011-10-21 2013-05-31 Abbvie Inc Métodos para el tratamiento de hcv
DE202012012956U1 (de) 2011-10-21 2014-10-16 Abbvie Inc. Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon
KR20150013152A (ko) 2012-05-07 2015-02-04 노파르티스 아게 알리스포리비르를 이용한 약동학적 조절
AR090964A1 (es) * 2012-05-09 2014-12-17 Novartis Ag Proceso para la elaboracion de undecapeptidos ciclicos
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
EP3038626A4 (de) 2013-08-26 2017-04-19 Enanta Pharmaceuticals, Inc. Cyclosporinanaloga zur prävention oder behandlung von hepatitis-c-infektionen
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US11807664B2 (en) 2017-05-12 2023-11-07 Chugai Seiyaku Kabushiki Kaisha Method for producing cyclic organic compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
USRE40987E1 (en) * 1998-07-01 2009-11-17 Debiopharm S.A. Cyclosporin with improved activity profile
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20090081164A1 (en) 2009-03-26
US20060252675A1 (en) 2006-11-09
DK1793844T3 (da) 2011-03-21
HRP20110169T1 (hr) 2011-04-30
EP1793844A1 (de) 2007-06-13
MA28950B1 (fr) 2007-10-01
BRPI0515494A (pt) 2008-07-29
CN101056648B (zh) 2012-08-15
CN101056648A (zh) 2007-10-17
JP2008514690A (ja) 2008-05-08
JP4892486B2 (ja) 2012-03-07
KR101191833B1 (ko) 2012-10-16
USRE43371E1 (en) 2012-05-08
AU2005290984B2 (en) 2010-09-09
ZA200702610B (en) 2008-08-27
TNSN07084A1 (en) 2008-06-02
US7439227B2 (en) 2008-10-21
IL182362A0 (en) 2007-07-24
SG139750A1 (en) 2008-02-29
SI1793844T1 (sl) 2011-05-31
CY1114594T1 (el) 2016-10-05
RS51614B (en) 2011-08-31
AU2005290984A1 (en) 2006-04-13
ATE490778T1 (de) 2010-12-15
NZ554412A (en) 2011-01-28
EA012650B1 (ru) 2009-12-30
EA200700725A1 (ru) 2007-10-26
US7772184B2 (en) 2010-08-10
MX2007003387A (es) 2007-05-23
UA88484C2 (ru) 2009-10-26
CA2580448C (en) 2012-09-18
PT1793844E (pt) 2011-03-10
EP1793844B1 (de) 2010-12-08
GEP20104960B (en) 2010-04-26
KR20070073761A (ko) 2007-07-10
CA2580448A1 (en) 2006-04-13
ES2357587T3 (es) 2011-04-27
HK1104236A1 (en) 2008-01-11
WO2006038088A1 (en) 2006-04-13
PL1793844T3 (pl) 2011-05-31

Similar Documents

Publication Publication Date Title
ATE490778T1 (de) Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion
ATE497775T1 (de) Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
WO2006033995A3 (en) Thiazolidin-4-ones having anti-hepatitis b activity
DE60119784D1 (de) Cyclische salen metall verbindungen als einfänger von sauerstoffradikalen und verwendbar als antioxidantien bei der behandlung und vorbeugung von krankheiten
EA200870019A1 (ru) Лактамовые соединения и способы их применения
WO2006138418A3 (en) Improvement of cognitive performance with sirtuin activators
EA200700243A1 (ru) Способы лечения гепатита с
DE602007004615D1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
DE602005012276D1 (de) Verwendung von probiotischen bakterien zur herstellung von topischen zusammensetzungen zum schutz der haut
ATE251942T1 (de) Stapelbare statische mischelemente
TW200640482A (en) Variant forms of urate oxidase and use thereof
ATE538790T1 (de) Scopolamin für die behandlung von depression und ängstlichkeit
WO2007092645A3 (en) Novel hcv inhibitor combinations and methods
DE60137978D1 (de) Zusammensetzung zur förderung des haarwachstums
DE60015568D1 (de) Zusammensetzungen zur behandlung von viralen infektionen und verfahren dafür
DK1147088T3 (da) 6-arylphenanthridiner med PDE-IV-inhiberende aktivitet
WO2006096769A3 (en) Use of alpha-glucosidase inhibitors to treat alphavirus infections
WO2005009366A3 (en) Restoring vascular function
ATE493176T1 (de) Verwendung von 3-positions-cyclosporin-derivaten für haarwachstum
EA200601392A1 (ru) Способы и композиции для лечения липодистрофии
WO2006127514A3 (en) Compositions and methods for treating hiv infection with cupredoxin and cytochrome c
WO2007021933A3 (en) Methods and compositions for use in treating vascular diseases and conditions
DE60229624D1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion